Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AAD 2025: Advancements in Dermatology : Episode 3
Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead
A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.
EP: 1.Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
EP: 2.AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics
Now Viewing
EP: 3.Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead
EP: 4.Ruxolitinib Cream and Atopic Dermatitis at AAD 2025
EP: 5.JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks
EP: 6.From AAD 2025 to the Future: Advancements in Dermatology to Watch
- What challenges do you anticipate in maintaining high treatment adherence rates for psoriasis therapies?
- With increasing availability of targeted biologic therapies, how do you anticipate treatment strategies for psoriasis will continue to evolve?
Related Videos
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
